Friday, April 19, 2024
Home Biotech News Stem Cells

Stem Cells

    Random

    Citius Pharma (CTXR) Updates Shareholders.

    CoronaVirus Editor / Curator -
    Citius Update Stem Cell Study Citius Pharmaceuticals, Inc announced that it will present a poster at the International Society...
    Issam Radd

    Citius Pharma (CTXR) Shareholder Letter | Year Ahead Roadmap.

    2020 Watch List Editor / Curator -
    2021 and 2020 Milestones In Plain Sight. Locked and Loaded for most of 2020 - many major milestone...
    Issam Radd

    Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).

    2021 Watch List Editor / Curator -
    Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR) Summary
    Internet Stock Review

    Stocks On The Move!

    Stem Cells Editor / Curator -
    Citius (CTXR) up 19%, Draganfly (DFLYF) up 31%, urban-gro (UGRO) up 37%, Provention (PVRB) flip-flopping, Hapbee Technologies (HAPBF) up 26% and the...

    Video: Mel Gibson Stem Cell Testimonial.

    Stem Cells Editor / Curator -
    Fascinating Interview with Joe Rogen, Mel Gibson, and Dr. Neil Riordan, Early Pioneer and Stem Cell Expert. Joe Rogan...
    Stem Cell Stock Review

    Old News, But Wow: Starr Foundation Reaffirms Support for Stem Cell Research with $50...

    Stem Cells Editor / Curator -
    Someone is a Big Believer and Cutting Equally Big Checks! NEW YORK (April 4, 2019) — The Starr...
    Biotech Stock Review. Citius, CTXR

    More Great News From Citius Pharma (CTXR).

    Incubator Editor / Curator -
    UPDATED CHART 6-15-21 Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News
    Citius, Leonard Mazur

    Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.

    Stem Cells Editor / Curator -
    https://youtu.be/vMIy8xWLOKI?t=3699 Starts at 1 Hour Mark. INSIDER HOLDINGS
    Biotech Stock Review

    Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.

    2021 Watch List Editor / Curator -
    Added to Watch List November 2019 @$0.55. Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...
    Internet Stock Review

    Newsletter: Institutional Analyst. And Yes, We Have Another Double.

    Institutional Analyst Newsletter Editor / Curator -
    1. Dalrada (DFCO) $0.19. And Yes, We Have Another Double!2. Dyadic (DYAI) $6.40. We're Up 392%, Video Presentation.3....
    123Page 1 of 3

    Latest article

    Experts From Harvard, Scripps Research Institute, the University Hospital Zürich, and the Former Chief...

    All News Editor / Curator -
    Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody...

    Major Mpox Outbreak in the Democratic Republic of Congo.

    Mpox Editor / Curator -
    As Reported in NPR's Gates and Soda Major Mpox Outbreak in the Democratic Republic of Congo is a...

    Mpox Infections Rise to Almost Double Last Year’s Numbers.

    All News Editor / Curator -
    The number of mpox cases in 2024 is already nearly double the number of cases that were detected in all of...
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.